Low-molecular-weight polymer–drug conjugates for synergistic anticancer activity of camptothecin and doxorubicin combinations
KM Camacho, S Menegatti, S Mitragotri - Nanomedicine, 2016 - Future Medicine
Background: High-molecular-weight (MW) polymers (> 50,000 Da) can be conjugated to
chemotherapy drugs in order to improve their tumor accumulation, while low MW polymers≤ …
chemotherapy drugs in order to improve their tumor accumulation, while low MW polymers≤ …
Low-Molecular-Weight Polymer–Drug Conjugates for Synergistic Anticancer Activity of Camptothecin and Doxorubicin Combinations
KM Camacho, S Menegatti, S Mitragotri - Nanomedicine, 2016 - Taylor & Francis
Background: High-molecular-weight (MW) polymers (> 50,000 Da) can be conjugated to
chemotherapy drugs in order to improve their tumor accumulation, while low MW polymers≤ …
chemotherapy drugs in order to improve their tumor accumulation, while low MW polymers≤ …
Low-molecular-weight polymer-drug conjugates for synergistic anticancer activity of camptothecin and doxorubicin combinations
KM Camacho, S Menegatti… - Nanomedicine …, 2016 - pubmed.ncbi.nlm.nih.gov
Background High-molecular-weight (MW) polymers (> 50,000 Da) can be conjugated to
chemotherapy drugs in order to improve their tumor accumulation, while low MW polymers≤ …
chemotherapy drugs in order to improve their tumor accumulation, while low MW polymers≤ …
Low-molecular-weight polymer-drug conjugates for synergistic anticancer activity of camptothecin and doxorubicin combinations.
KM Camacho, S Menegatti… - Nanomedicine (London …, 2016 - europepmc.org
Background High-molecular-weight (MW) polymers (> 50,000 Da) can be conjugated to
chemotherapy drugs in order to improve their tumor accumulation, while low MW polymers≤ …
chemotherapy drugs in order to improve their tumor accumulation, while low MW polymers≤ …
Low-molecular-weight polymer–drug conjugates for synergistic anticancer activity of camptothecin and doxorubicin combinations
KM Camacho, S Menegatti, S Mitragotri - Nanomedicine, 2016 - cir.nii.ac.jp
抄録< jats: p> Background: High-molecular-weight (MW) polymers (> 50,000 Da) can be
conjugated to chemotherapy drugs in order to improve their tumor accumulation, while low …
conjugated to chemotherapy drugs in order to improve their tumor accumulation, while low …
[HTML][HTML] Low-molecular-weight polymer–drug conjugates for synergistic anticancer activity of camptothecin and doxorubicin combinations
KM Camacho, S Menegatti, S Mitragotri - Nanomedicine, 2016 - ncbi.nlm.nih.gov
Background: High-molecular-weight (MW) polymers (> 50,000 Da) can be conjugated to
chemotherapy drugs in order to improve their tumor accumulation, while low MW polymers≤ …
chemotherapy drugs in order to improve their tumor accumulation, while low MW polymers≤ …
Low-molecular-weight polymer–drug conjugates for synergistic anticancer activity of camptothecin and doxorubicin combinations
KM Camacho, S Menegatti, S Mitragotri - Nanomedicine, 2016 - search.proquest.com
Background: High-molecular-weight (MW) polymers (> 50,000 Da) can be conjugated to
chemotherapy drugs in order to improve their tumor accumulation, while low MW polymers≤ …
chemotherapy drugs in order to improve their tumor accumulation, while low MW polymers≤ …
Low-molecular-weight polymer-drug conjugates for synergistic anticancer activity of camptothecin and doxorubicin combinations.
KM Camacho, S Menegatti… - Nanomedicine (London …, 2016 - europepmc.org
Background High-molecular-weight (MW) polymers (> 50,000 Da) can be conjugated to
chemotherapy drugs in order to improve their tumor accumulation, while low MW polymers≤ …
chemotherapy drugs in order to improve their tumor accumulation, while low MW polymers≤ …